TY - JOUR T1 - Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. JF - The Journal of Rheumatology JO - J Rheumatol SP - 2372 LP - 2375 VL - 33 IS - 12 AU - Theodore Pincus AU - Yusuf Yazici AU - Ronald van Vollenhoven Y1 - 2006/12/01 UR - http://www.jrheum.org/content/33/12/2372.abstract N2 - 300 Multiple ChoicesThis is a pdf-only article and there is no markup to show you.full-text.pdf ER -